Browse EIF3CL

Summary
SymbolEIF3CL
Nameeukaryotic translation initiation factor 3, subunit C-like
Aliases eukaryotic translation initiation factor 3, subunit 8, 110kDa-like; Eukaryotic translation initiation factor ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain PF05470 Eukaryotic translation initiation factor 3 subunit 8 N-terminus
PF01399 PCI domain
Function

Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein synthesis. The eIF-3 complex associates with the 40S ribosome and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-tRNAi and eIF-5 to form the 43S pre-initiation complex (43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for disassembly and recycling of post-termination ribosomal complexes and subsequently prevents premature joining of the 40S and 60S ribosomal subunits prior to initiation. The eIF-3 complex specifically targets and initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-loop binding to exert either translational activation or repression.

> Gene Ontology
 
Biological Process GO:0001731 formation of translation preinitiation complex
GO:0006413 translational initiation
GO:0006417 regulation of translation
GO:0006446 regulation of translational initiation
GO:0010608 posttranscriptional regulation of gene expression
GO:0022613 ribonucleoprotein complex biogenesis
GO:0022618 ribonucleoprotein complex assembly
GO:0034248 regulation of cellular amide metabolic process
GO:0071826 ribonucleoprotein complex subunit organization
Molecular Function GO:0003743 translation initiation factor activity
GO:0008135 translation factor activity, RNA binding
GO:0031369 translation initiation factor binding
Cellular Component GO:0005852 eukaryotic translation initiation factor 3 complex
GO:0016282 eukaryotic 43S preinitiation complex
GO:0033290 eukaryotic 48S preinitiation complex
GO:0070993 translation preinitiation complex
> KEGG and Reactome Pathway
 
KEGG hsa03013 RNA transport
Reactome -
Summary
SymbolEIF3CL
Nameeukaryotic translation initiation factor 3, subunit C-like
Aliases eukaryotic translation initiation factor 3, subunit 8, 110kDa-like; Eukaryotic translation initiation factor ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EIF3CL and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolEIF3CL
Nameeukaryotic translation initiation factor 3, subunit C-like
Aliases eukaryotic translation initiation factor 3, subunit 8, 110kDa-like; Eukaryotic translation initiation factor ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EIF3CL in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolEIF3CL
Nameeukaryotic translation initiation factor 3, subunit C-like
Aliases eukaryotic translation initiation factor 3, subunit 8, 110kDa-like; Eukaryotic translation initiation factor ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EIF3CL in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.280.574
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5640.531
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0830.905
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9162.2570.0686
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592.6780.116
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.7420.404
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.2490.0222
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.760.0281
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.810.351
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0730.972
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3320.912
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1810.0651
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolEIF3CL
Nameeukaryotic translation initiation factor 3, subunit C-like
Aliases eukaryotic translation initiation factor 3, subunit 8, 110kDa-like; Eukaryotic translation initiation factor ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EIF3CL. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEIF3CL
Nameeukaryotic translation initiation factor 3, subunit C-like
Aliases eukaryotic translation initiation factor 3, subunit 8, 110kDa-like; Eukaryotic translation initiation factor ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EIF3CL. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EIF3CL.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEIF3CL
Nameeukaryotic translation initiation factor 3, subunit C-like
Aliases eukaryotic translation initiation factor 3, subunit 8, 110kDa-like; Eukaryotic translation initiation factor ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EIF3CL. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEIF3CL
Nameeukaryotic translation initiation factor 3, subunit C-like
Aliases eukaryotic translation initiation factor 3, subunit 8, 110kDa-like; Eukaryotic translation initiation factor ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EIF3CL expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEIF3CL
Nameeukaryotic translation initiation factor 3, subunit C-like
Aliases eukaryotic translation initiation factor 3, subunit 8, 110kDa-like; Eukaryotic translation initiation factor ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EIF3CL and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEIF3CL
Nameeukaryotic translation initiation factor 3, subunit C-like
Aliases eukaryotic translation initiation factor 3, subunit 8, 110kDa-like; Eukaryotic translation initiation factor ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EIF3CL collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.